메뉴 건너뛰기




Volumn 17, Issue 3, 2011, Pages 236-245

Drug interactions in metastatic breast cancer

Author keywords

biologic therapy; chemotherapy; drug interactions; metastatic breast cancer; oral administration

Indexed keywords

ANASTROZOLE; ANTACID AGENT; AROMATASE INHIBITOR; BROMOCRIPTINE; CAPECITABINE; CIMETIDINE; CISPLATIN; COUMARIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ESTROGEN; IXABEPILONE; LAPATINIB; MEDROXYPROGESTERONE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDOREDUCTASE INHIBITOR; PACLITAXEL; PHENYTOIN; PROGESTERONE; RAZOXANE; SUXAMETHONIUM; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

EID: 80053323258     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155210379167     Document Type: Review
Times cited : (6)

References (50)
  • 3
    • 80053304479 scopus 로고    scopus 로고
    • Wilmington, DE: AstraZeneca Pharmaceuticals LP
    • Faslodex (fulvestrant) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2005.
    • (2005) Faslodex (Fulvestrant) [Package Insert]
  • 11
    • 74549146408 scopus 로고    scopus 로고
    • Princeton, NJ: Bristol-Myers Squibb Company
    • Ixempra (ixabepilone) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2009.
    • (2009) Ixempra (Ixabepilone) [Package Insert]
  • 12
    • 0011475181 scopus 로고    scopus 로고
    • Princeton, NJ : Bristol-Myers Squibb Company
    • Taxol (paclitaxel) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2007.
    • (2007) Taxol (Paclitaxel) [Package Insert]
  • 15
    • 80052503758 scopus 로고    scopus 로고
    • Research Triangle Park, NC: GlaxoSmithKline
    • Tykerb (lapatinib) [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2008.
    • (2008) Tykerb (Lapatinib) [Package Insert]
  • 17
    • 43949096582 scopus 로고    scopus 로고
    • Inflammation and altered drug clearance in cancer: Transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice
    • DOI 10.1038/clpt.2008.55, PII CLPT200855
    • Robertson GR, Liddle C. and Clarke SJ Inflammation; altered drug clearance in cancer: Transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice. Clin Pharmacol Ther 2008 ; 83: 894-897. (Pubitemid 351704929)
    • (2008) Clinical Pharmacology and Therapeutics , vol.83 , Issue.6 , pp. 894-897
    • Robertson, G.R.1    Liddle, C.2    Clarke, S.J.3
  • 18
    • 33745574979 scopus 로고    scopus 로고
    • Drug interactions in cancer therapy
    • DOI 10.1038/nrc1887, PII N1887
    • Scripture CD and Figg WD Drug interactions in cancer therapy. Nat Rev Cancer 2006 ; 6: 546-558. (Pubitemid 43980543)
    • (2006) Nature Reviews Cancer , vol.6 , Issue.7 , pp. 546-558
    • Scripture, C.D.1    Figg, W.D.2
  • 19
    • 0002367230 scopus 로고    scopus 로고
    • Principles of Therapeutics
    • Hardman J, Limbird LE and Molinoff PB (eds) 9th edn. New York, NY: The McGraw-Hill Companies
    • Nies A. and Spielberg SP Principles of therapeutics. In: Hardman J, Limbird LE and Molinoff PB (eds) Goodman and Gilman's the pharmacological basis of therapeutics, 9 th edn. New York, NY: The McGraw-Hill Companies, 1996, p. 43-45.
    • (1996) Goodman and Gilman's the Pharmacological Basis of Therapeutics , pp. 43-45
    • Nies, A.1    Spielberg, S.P.2
  • 21
    • 0034851464 scopus 로고    scopus 로고
    • Clinical-pharmacological strategies to assess drug interaction potential during drug development
    • Kuhlmann J. and Muck W. Clinical-pharmacological strategies to assess drug interaction potential during drug development. Drug Saf 2001 ; 24: 715-725. (Pubitemid 32848351)
    • (2001) Drug Safety , vol.24 , Issue.10 , pp. 715-725
    • Kuhlmann, J.1    Muck, W.2
  • 22
    • 33745524017 scopus 로고    scopus 로고
    • Drug Interactions in Cancer Therapy: Pharmacodynamic Drug Interactions
    • Figg WD and McLeod HL (eds) Totowa, NJ: Humana Press
    • Ando Y. Drug interactions in cancer therapy: Pharmacodynamic drug interactions. In: Figg WD and McLeod HL (eds) Handbook of anticancer pharmacokinetics and pharmacodynamics. Totowa, NJ: Humana Press, 2004, p. 215-230.
    • (2004) Handbook of Anticancer Pharmacokinetics and Pharmacodynamics , pp. 215-230
    • Ando, Y.1
  • 23
    • 10944253706 scopus 로고    scopus 로고
    • Effects of food on the clinical pharmacokinetics of anticancer agents: Underlying mechanisms and implications for oral chemotherapy
    • DOI 10.2165/00003088-200443150-00005
    • Singh BN and Malhotra BK Effects of food on the clinical pharmacokinetics of anticancer agents: Underlying mechanisms and implications for oral chemotherapy. Clin Pharmacokinet 2004 ; 43: 1127-1156. (Pubitemid 40013180)
    • (2004) Clinical Pharmacokinetics , vol.43 , Issue.15 , pp. 1127-1156
    • Singh, B.N.1    Malhotra, B.K.2
  • 24
    • 2942729844 scopus 로고    scopus 로고
    • Herbal remedies in the United States: Potential adverse interactions with anticancer agents
    • DOI 10.1200/JCO.2004.08.182
    • Sparreboom A., Cox MC, Acharya MR and Figg WD Herbal remedies in the United States: Potential adverse interactions with anticancer agents. J Clin Oncol 2004 ; 22: 2489-2503. (Pubitemid 41115408)
    • (2004) Journal of Clinical Oncology , vol.22 , Issue.12 , pp. 2489-2503
    • Sparreboom, A.1    Cox, M.C.2    Acharya, M.R.3    Figg, W.D.4
  • 29
    • 37449028688 scopus 로고    scopus 로고
    • Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
    • Forbes JF, Cuzick J., Buzdar A., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008 ; 9: 45-53.
    • (2008) Lancet Oncol , vol.9 , pp. 45-53
    • Forbes, J.F.1    Cuzick, J.2    Buzdar, A.3
  • 32
    • 69949106198 scopus 로고    scopus 로고
    • Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy
    • Bansal T., Jaggi M., Khar RK and Talegaonkar S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 2009 ; 12: 46-78.
    • (2009) J Pharm Pharm Sci , vol.12 , pp. 46-78
    • Bansal, T.1    Jaggi, M.2    Khar, R.K.3    Talegaonkar, S.4
  • 34
    • 15744405556 scopus 로고    scopus 로고
    • The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: Evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5
    • DOI 10.1124/jpet.104.079608
    • Lin HL, Kent UM and Hollenberg PF The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: Evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5. J Pharmacol Exp Ther 2005 ; 313: 154-164. (Pubitemid 40411339)
    • (2005) Journal of Pharmacology and Experimental Therapeutics , vol.313 , Issue.1 , pp. 154-164
    • Lin, H.-L.1    Kent, U.M.2    Hollenberg, P.F.3
  • 35
    • 0034954793 scopus 로고    scopus 로고
    • Inhibition of P-glycoprotein transport function by grapefruit juice psoralen
    • DOI 10.1023/A:1011089924099
    • Wang EJ, Casciano CN, Clement RP and Johnson WW Inhibition of P-glycoprotein transport function by grapefruit juice psoralen. Pharm Res 2001 ; 18: 432-438. (Pubitemid 32592573)
    • (2001) Pharmaceutical Research , vol.18 , Issue.4 , pp. 432-438
    • Wang, E.-J.1    Casciano, C.N.2    Clement, R.P.3    Johnson, W.W.4
  • 36
    • 11844301652 scopus 로고    scopus 로고
    • Effects of dietary chemopreventive phytochemicals on P-glycoprotein function
    • DOI 10.1016/j.bbrc.2004.12.081, PII S0006291X04028736
    • Nabekura T., Kamiyama S. and Kitagawa S. Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochem Biophys Res Commun 2005 ; 327: 866-870. (Pubitemid 40092828)
    • (2005) Biochemical and Biophysical Research Communications , vol.327 , Issue.3 , pp. 866-870
    • Nabekura, T.1    Kamiyama, S.2    Kitagawa, S.3
  • 37
    • 28244477789 scopus 로고    scopus 로고
    • Effects of St. John's wort and hypericin on cytotoxicity of anticancer drugs
    • Wada A., Sakaeda T., Takara K., et al. Effects of St. John's wort and hypericin on cytotoxicity of anticancer drugs. Drug Metab Pharmacokinet 2002 ; 17: 467-474.
    • (2002) Drug Metab Pharmacokinet , vol.17 , pp. 467-474
    • Wada, A.1    Sakaeda, T.2    Takara, K.3
  • 38
    • 66949155833 scopus 로고    scopus 로고
    • Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors
    • Golden EB, Lam PY, Kardosh A., et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood 2009 ; 113: 5927-5937.
    • (2009) Blood , vol.113 , pp. 5927-5937
    • Golden, E.B.1    Lam, P.Y.2    Kardosh, A.3
  • 39
    • 0033999331 scopus 로고    scopus 로고
    • Drug interactions in palliative care
    • Bernard SA and Bruera E. Drug interactions in palliative care. J Clin Oncol 2000 ; 18: 1780-1799. (Pubitemid 30220558)
    • (2000) Journal of Clinical Oncology , vol.18 , Issue.8 , pp. 1780-1799
    • Bernard, S.A.1    Bruera, E.2
  • 40
    • 45249121177 scopus 로고    scopus 로고
    • Drugs behave as substrates, inhibitors and inducers of human cytochrome
    • Zhou SF Drugs behave as substrates, inhibitors and inducers of human cytochrome. P450 3A4 Curr Drug Metab 2008 ; 9: 310-322.
    • (2008) P450 3A4 Curr Drug Metab , vol.9 , pp. 310-322
    • Zhou, S.F.1
  • 41
    • 44449112267 scopus 로고    scopus 로고
    • Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4
    • Zhou SF Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4. Curr Pharm Des 2008 ; 14: 990-1000.
    • (2008) Curr Pharm des , vol.14 , pp. 990-1000
    • Zhou, S.F.1
  • 42
    • 70349328422 scopus 로고    scopus 로고
    • No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications
    • Ahern TP, Pedersen L., Cronin-Fenton D., et al. No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol Biomarkers Prev 2009 ; 18: 2562.
    • (2009) Cancer Epidemiol Biomarkers Prev , vol.18 , pp. 2562
    • Ahern, T.P.1    Pedersen, L.2    Cronin-Fenton, D.3
  • 43
    • 34248208754 scopus 로고    scopus 로고
    • Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
    • Wegman P., Elingarami S., Carstensen J., et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007 ; 9: R7.
    • (2007) Breast Cancer Res , vol.9 , pp. 7
    • Wegman, P.1    Elingarami, S.2    Carstensen, J.3
  • 44
    • 62749188875 scopus 로고    scopus 로고
    • Role of ATP-binding cassette (ABC) transporters in interactions between natural products and drugs
    • Aszalos A. Role of ATP-binding cassette (ABC) transporters in interactions between natural products and drugs. Curr Drug Metab 2008 ; 9: 1010-1018.
    • (2008) Curr Drug Metab , vol.9 , pp. 1010-1018
    • Aszalos, A.1
  • 45
    • 58149127453 scopus 로고    scopus 로고
    • Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy
    • Suzuki K., Doki K., Homma M., et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 2008 ; 67: 44-49.
    • (2008) Br J Clin Pharmacol , vol.67 , pp. 44-49
    • Suzuki, K.1    Doki, K.2    Homma, M.3
  • 46
    • 0036218554 scopus 로고    scopus 로고
    • Changes in plasma protein binding have little clinical relevance
    • DOI 10.1067/mcp.2002.121829
    • Benet LZ and Hoener BA Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002 ; 71: 115-121. (Pubitemid 34271114)
    • (2002) Clinical Pharmacology and Therapeutics , vol.71 , Issue.3 , pp. 115-121
    • Benet, L.Z.1    Hoener, B.-A.2
  • 47
    • 0035033019 scopus 로고    scopus 로고
    • Pharmacogenomics: Unlocking the human genome for better drug therapy
    • DOI 10.1146/annurev.pharmtox.41.1.101
    • McLeod HL and Evans WE Pharmacogenomics: Unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001 ; 41: 101-121. (Pubitemid 32385884)
    • (2001) Annual Review of Pharmacology and Toxicology , vol.41 , pp. 101-121
    • McLeod, H.L.1    Evans, W.E.2
  • 48
    • 17244364722 scopus 로고    scopus 로고
    • Assessing medication adherence in the elderly
    • MacLaughlin EJ, Raehl CL, Treadway AK, et al. Assessing medication adherence in the elderly. Drugs Aging 2005 ; 22: 231-255.
    • (2005) Drugs Aging , vol.22 , pp. 231-255
    • MacLaughlin, E.J.1    Raehl, C.L.2    Treadway, A.K.3
  • 49
    • 65649099099 scopus 로고    scopus 로고
    • Effect of an electronic medication reconciliation application and process redesign on potential adverse drug events: A cluster-randomized trial
    • Schnipper JL, Hamann C., Ndumele CD, et al. Effect of an electronic medication reconciliation application and process redesign on potential adverse drug events: A cluster-randomized trial. Arch Intern Med 2009 ; 169: 771-780.
    • (2009) Arch Intern Med , vol.169 , pp. 771-780
    • Schnipper, J.L.1    Hamann, C.2    Ndumele, C.D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.